RxDoctor Payments Data

Lauren Cooper

Family Medicine · Carthage, TNNPI 1174919617

Payments from drug & device makers

$3,968in general payments, 2019–2025

Across 245 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$512
  • AstraZeneca$336
  • GSK$257
  • Pfizer$159
  • Amgen$114
  • plus $1K from 38 others

What the payments were for

  • Food & beverage$3,86097%
  • Other$1083%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,968 in reported general payments places this provider in the 75th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$25,624
Medicare patients
135
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$91,218
OzempicSemaglutide83$90,429
MounjaroTirzepatide43$44,680
TrulicityDulaglutide43$43,956
VraylarCariprazine Hcl30$42,460
JardianceEmpagliflozin44$36,074
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$33,565
XareltoRivaroxaban46$31,755
LinzessLinaclotide53$28,941
JanuviaSitagliptin Phosphate32$28,855
FarxigaDapagliflozin Propanediol25$19,609
TradjentaLinagliptin31$17,783
MyrbetriqMirabegron34$15,119
GemtesaVibegron21$13,613
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$12,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$159$91,218138 claims
Novo NordiskOzempic$1,244$90,42983 claims
Lilly USA, LLCMounjaro, Trulicity$59$88,63686 claims
AbbVieVraylar, Linzess$512$71,40183 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$17$62,89191 claims
GSKTrelegy Ellipta, Anoro Ellipta$257$46,06168 claims
AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere$336$39,03058 claims
MerckJanuvia, Belsomra$27$34,22244 claims
Johnson & JohnsonXarelto$98$31,75546 claims
Sumitomo Pharma America, Inc.Gemtesa$59$13,61321 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$24$7,86321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Carthage

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →